. 2020 Jul 29;27(3):1073274820944286. doi: 10.1177/1073274820944286

Table 4.

Distributions of NPC Patients by Overall Clinical Stages and Relationships with their EBV DNA Levels.

Variable	No. of patients (N = 152)	Undetectable EBV DNA, n (%)	EBV DNA (copies/mL)			P value^a
Variable	No. of patients (N = 152)	Undetectable EBV DNA, n (%)	<300 copies/mL, n (%)	≥300 copies/mL, n (%)	Mean ± SE (range)	P value^a
Stage I and II	46	2 (4.3%)	13 (28.3%)	31 (67.4%)	6920 ± 2314 (0-73 000 copies/mL)	.016
Stage III and IV	106	2 (1.9%)	22 (20.8%)	82 (77.4%)	15 116 ± 4299 (0-383 000 copies/mL)	.016

Abbreviations: EBV, Epstein Barr virus; NPC, nasopharyngeal carcinoma; SE, standard error.

^a Comparison was performed using Pearson χ² test.